LexaGene Engages Contract Manufacturer to Support Product Launch
August 17 2020 - 7:58AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems, is
pleased to announce it has engaged LaunchWorks to support the
commercial launch of MiQLab™ prior to the end of September 2020.
Launchworks is an FDA registered, ISO 13485 certified, cGMP
compliant contract manufacturer specializing in manufacturing
consumables for life science companies. Launchworks will
manufacture the assay panels and buffer sets used in LexaGene’s
fully automated MiQLab system, which will provide rapid test
results inside clinics and hospitals to help eliminate the current
wait times of one to several days for reference laboratory
generated test results.
Dr. Jack Regan, LexaGene’s CEO and Founder, states, “We are
making great progress in adding sales and manufacturing to
LexaGene’s capabilities. I’m very pleased to announce our
partnership with LaunchWorks, which will be responsible for
manufacturing the consumables required to operate MiQLab.
Launchworks can currently manufacture enough products to easily
support our commercial launch and have the facilities to scale
their production to meet any demands that we require. I am very
impressed by their facilities, high caliber staff, and their
ability to scale their operations to meet our needs as we
grow.”
Daryl Rebeck, LexaGene’s President and Co-Founder, adds, “This
is an extremely exciting time for LexaGene. Our initial hires in
sales are working out exceedingly well and we are in the home
stretch for manufacturing and qualification. By the end of next
month, we expect to begin selling and fulfilling delivery of our
first units, which will be a huge milestone for the Company.”
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of Directors Dr. Jack Regan Chief
Executive Officer & Director
About LexaGene Holdings Inc. LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately one
hour. The unique open-access feature is designed for custom testing
so that end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
For further information, please contact:
Media Contacts Nicole Ridgedale Director of
Corporate Marketing, LexaGene800.215.1824 ext
206nridgedale@lexagene.com
Investor Relations Jay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024